Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.

BACKGROUND: Evidence for efficacy of disease-modifying drugs in multiple sclerosis (MS) comes from trials of short duration. We report results from a 16 y, retrospective follow-up of the pivotal interferon beta-1b (IFNB-1b) study. METHODS: The 372 trial patients were randomly assigned to placebo (n=...

Full description

Bibliographic Details
Main Authors: Ebers, G, Traboulsee, A, Li, D, Langdon, D, Reder, A, Goodin, D, Bogumil, T, Beckmann, K, Wolf, C, Konieczny, A
Format: Journal article
Language:English
Published: 2010

Similar Items

Similar Items